Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations
dc.contributor.author | Ayres, James W. | en_US |
dc.contributor.author | Stoll, Roger G. | en_US |
dc.contributor.author | Sakmar, Ermelinda | en_US |
dc.contributor.author | Hallmark, Margarette R. | en_US |
dc.contributor.author | Wagner, John G. | en_US |
dc.contributor.author | Weidler, Donald J. | en_US |
dc.date.accessioned | 2006-09-11T15:38:40Z | |
dc.date.available | 2006-09-11T15:38:40Z | |
dc.date.issued | 1979-04 | en_US |
dc.identifier.citation | Wagner, J. G.; Stoll, R. G.; Weidler, D. J.; Ayres, J. W.; Hallmark, M. R.; Sakmar, E.; (1979). "Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations." Journal of Pharmacokinetics and Biopharmaceutics 7(2): 147-158. <http://hdl.handle.net/2027.42/45076> | en_US |
dc.identifier.issn | 0090-466X | en_US |
dc.identifier.issn | 1573-8744 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45076 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=20218011&dopt=citation | en_US |
dc.description.abstract | A blinded, four-treatment crossover study in 16 normal adult male volunteers compared plasma concentrations and urinary excretion of digoxin, measured by radioimmunoassay, after oral administration of soft gelatin capsule formulations of digoxin. Four 0.4-mg formulations with different in vitro “burst times” and dissolution rates were administered, with 2- week intervals between treatments. The two capsules with lowest in vitro burst times (2.9 and 16 min) gave comparable in vivo results. The other two capsules, with in vitro burst times of 62 and 229 min, produced significant delays in digoxin absorption . In vitro-in vivo correlations were obtained by comparing the logarithm of the in vitro burst time with time to peak plasma level and the time to the first measurable plasma level (≥ 0.05 ng/ml). Also, the mean time to peak plasma level correlated with the logarithm of the time required to release either 50% or 85% of the digoxin in vitro. No significant changes were found in the amount of digoxin absorbed from each capsule as determined by urinary excretion or AUC 0-∞ . | en_US |
dc.format.extent | 530956 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Correlations | en_US |
dc.subject.other | Digoxin Bioavailability | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Veterinary Medicine | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | In Vitro-in Vivo | en_US |
dc.subject.other | Digoxin Radioimmunoassay | en_US |
dc.subject.other | Plasma Concentrations and Urinary Excretion of Digoxin | en_US |
dc.subject.other | Gelatin Capsule Formulations | en_US |
dc.title | Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Internal Medicine and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michigan; School of Pharmacy, Oregon State University, 97331, Corvallis, Oregon | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, 48109, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Biopharmaceutical Sciences, Arnar-Stone Laboratories, Inc., 60085, McGraw Park, Illinois | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 20218011 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45076/1/10928_2005_Article_BF01059735.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF01059735 | en_US |
dc.identifier.source | Journal of Pharmacokinetics and Biopharmaceutics | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.